Peptide vaccines in immunocontraception

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 1, 2004, Pages 83-89

  Ferro, V A ^a   Mordini, E ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b Centre for Science Society and Citizenship   (Italy)

Author keywords

Antifertility; Contraceptive; Gametes; Hormones; Peptides; Vaccines

Indexed keywords

CARRIER PROTEIN; CONTRACEPTIVE VACCINE; FOLLITROPIN RECEPTOR; GONADORELIN RECEPTOR; LUTEINIZING HORMONE RECEPTOR; SUBUNIT VACCINE;

ANIMAL; CHEMISTRY; ETHICS; FEMALE; FORECASTING; HUMAN; IMMUNOCONTRACEPTION; IMMUNOLOGY; MALE; OOCYTE; REVIEW; SPERMATOZOON;

ANIMALS; CARRIER PROTEINS; CONTRACEPTION, IMMUNOLOGIC; FEMALE; FORECASTING; HUMANS; MALE; OOCYTES; RECEPTORS, FSH; RECEPTORS, LH; RECEPTORS, LHRH; SPERMATOZOA; VACCINES, CONTRACEPTIVE; VACCINES, SUBUNIT;

EID: 3843063664     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Baird DT: Overview of advances in contraception. Br Med Bull (2000) 56(3):704-716.
2. Aitken RJ: Immunocontraceptive vaccines for human use. J Reprod Immunol (2002) 57(1-2):273-287.
3. Lofthouse S, Kemp J: Manipulating the immune response; applications in livestock breeding. J Reprod Immunol (2002) 57(1-2):239-253.
4. Bradley MP, Eade J, Penhale J, Bird P: Vaccines for fertility regulation of wild and domestic species. J Biotechnol (1999) 73(2-3):91-101.
5. Thompson DL: Immunization against GnRH in male species (comparative aspects). Anim Reprod Sci (2000) 60-61:459-469.
6. Anderson RA, Baird DT: Male contraception. Endocr Rev (2002) 23(6):735-762.
7. McLaughlin EA, Holland MK, Aitken RJ: Contraceptive vaccines. Expert Opin Biol Ther (2003) 3(5):829-841.
8. Ferro VA: Current advances in antifertility vaccines for fertility control and noncontraceptive applications. Expert Rev Vaccines (2002) 1(4):443-452.
9. Frayne J, Hall L: The potential use of sperm antigens as targets for immunocontraception; past, present and future. J Reprod Immunol (1999) 43(1):1-33.
10. Gupta A, Pal R, Ahlawat S, Bhatia P, Singh O: Enhanced immunogenicity of a contraceptive vaccine using diverse synthetic carriers with permissible adjuvant. Vaccine (2001) 19(25-26):3384-3389.
11. Renjifo X, Wolf S, Pastoret PP, Bazin H, Urbain J, Leo O, Moser M: Carrier-induced, hapten-specific suppression: A problem of antigen presentation? J Immunol (1998) 161(2):702-706.
12. Dunbar BS, Kaul G, Prasad M, Skinner SM: Molecular approaches for the evaluation of immune responses to zona pellucida (ZP) and development of second-generation ZP vaccines. Reprod Suppl (2002) 60:9-18.
13. Sadler K, Zeng W, Jackson DC: Synthetic peptide epitope-based polymers: Controlling size and determining the efficiency of epitope incorporation. J Pept Res (2002) 60(3):150-158.
14. Sette A, Newman M, Livingston B, McKinney D, Sidney J, Ishioka G, Tangri S, Alexander J, Fikes J, Chesnut R: Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens (2002) 59(6):443-451.
15. Natraj U: Molecular approaches to contraceptive development. J Biosci (2001) 26(4 Suppl):407-419.
16. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC: Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol (2002) 169(9):4905-4912.
17. Fromme B, Eftekhari P, Van Regenmortel M, Hoebeke J, Katz A, Millar R: A novel retro-inverso gonadotropin-releasing hormone (GnRH) immunogen elicits antibodies that neutralize the activity of native GnRH. Endocrinology (2003) 144(7):3262-3269.
18. Abdennebi L, Couture L, Grebert D, Pajot E, Salesse R, Remy JJ: Generating FSH antagonists and agonists through immunization against FSH receptor N-terminal decapeptides. J Mol Endocrinol (1999) 22(2):151-159.
19. Ferro VA, Stimson WH: Immunoneutralisation of gonadotrophin releasing hormone: A potential treatment for oestrogen-dependent breast cancer. Eur J Cancer (1997) 33(9):1468-1478.
20. Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE, Bishop MC: Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br J Cancer (2000) 83(4):443-446.
21. Khan MA, Ferro VA, Stimson WH: Use of a highly specific monoclonal antibody against the central variable amino acid sequence of mammalian gonadotropin releasing hormone to evaluate GnRH-I tissue distribution compared with GnRH-I binding sites in adult male rats. Am J Reprod Immunol (2003) 49(4):239-248.
22. Temple JL, Millar RP, Rissman EF: An evolutionarily conserved form of gonadotropin-releasing hormone coordinates energy and reproductive behavior. Endocrinology (2003) 144(1):13-19.
23. McCann SM, Karanth S, Mastronardi CA, Dees WL, Childs G, Miller B, Sower S, Yu WH: Control of gonadotropin secretion by follicle-stimulating hormone-releasing factor, luteinizing hormone-releasing hormone, and leptin. Arch Med Res (2001) 32(6):476-485.
24. Ferro VA, Khan MA, Latimer VS, Brown D, Urbanski HF, Stimson WH: Immunoneutralisation of GnRH-I, without cross-reactivity to GnRH-II, in the development of a highly specific anti-fertility vaccine for clinical and veterinary use. J Reprod Immunol (2001) 51(2):109-129.
25. Talwar GP: Fertility regulating and immunotherapeutic vaccines reaching human trials stage. Hum Reprod Update (1997) 3(4):301-310.
26. Ferro VA, Stimson WH: Fertility-disrupting potential of synthetic peptides derived from the β-subunit of follicle-stimulating hormone. Am J Reprod Immunol (1998) 40(3):187-197.
27. Hillier SG: Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol (2001) 179(1-2):39-46.
28. Plant TM, Marshall GR: The functional significance of FSH in spermatogenesis and the control of its secretion in male primates. Endocr Rev (2001) 22(6):764-786.
29. Sharma RS, Rajalakshmi M, Jeyaraj DA: Current status of fertility control methods in India. J Biosci (2001) 26(4 Suppl):391-405.
30. Abdennebi L, Chun EY, Jammes H, Wei D, Remy JJ: Maintenance of sexual immaturity in male mice and bucks by immunization against N-terminal peptides of the follicle-stimulating hormone receptor. Biol Reprod (2003) 68(1):323-327.
31. Lindau-Shepard B, Brumberg HA, Peterson AJ, Dias JA: Reversible immunoneutralization of human follitropin receptor. J Reprod Immunol (2001) 49(1):1-19.
32. Delves PJ, Lund T, Roitt IM: Antifertility vaccines. Trends Immunol (2002) 23(4):213-219.
33. Vanage GR, Mehta PB, Moodbidri SB, Iyer KS: Effect of immunization with synthetic peptide corresponding to region 1-17 of human seminal plasma inhibin on fertility of male rats. Arch Androl (2000) 44(1):11-21.
34. Mate KE, Buist JM, Duckworth JA: Expression in Escherichia coli and immunological characterization of three zona pellucida proteins (ZP1, ZP2, and ZP3) from a marsupial, the brushtail possum (Trichosurus vulpecula). Mol Reprod Dev (2003) 64(2):136-143.
35. Naz RK, Leslie MH, Zhu X: Inhibition of murine sperm-oolemma binding by antibodies to an oocyte membrane (OM) antigen: Implication in contraceptive vaccine development. Am J Reprod Immunol (2001) 45(1):52-61.
36. Pomering M, Jones RC, Holland MK, Blake AE, Beagley KW: Restricted entry of IgG into male and female rabbit reproductive ducts following immunization with recombinant rabbit PH-20. Am J Reprod Immunol (2002) 47(3):174-182.
37. Grandi G: Antibacterial vaccine design using genomics and proteomics. Trends Biotechnol (2001) 19(5):181-188.
38. Gupta SK, Jethanandani P, Afzalpurkar A, Kaul R, Santhanam R: Prospects of zona pellucida glycoproteins as immunogens for contraceptive vaccine. Hum Reprod Update (1997) 3(4):311-324.
39. Paterson M, Jennings ZA, Wilson MR, Aitken RJ: The contraceptive potential of ZP3 and ZP3 peptides in a primate model. J Reprod Immunol (2002) 53(1-2):99-107.
40. Brown RG, Bowen WD, Eddington JD, Kimmins WC, Mezei M, Parsons JL, Pohajdak B: Evidence for a long-lasting single administration contraceptive vaccine in wild grey seals. J Reprod Immunol (1997) 35(1):43-51.
41. Kirkpatrick JF, Turner A: Reversibility of action and safety during pregnancy of immunization against porcine zona pellucida in wild mares (Equus caballus). Reprod Suppl (2002) 60:197-202.
42. Miller LA, Johns BE, Killian GJ: Immunocontraception of white-tailed deer with GnRH vaccine. Am J Reprod Immunol (2000) 44(5):266-274.
43. Subramanian S, Karande AA, Adiga PR: Immunocontraceptive potential of major antigenic determinants of chicken riboflavin carrier protein in the female rat. Vaccine (2000) 19(9-10):1172-1179.
44. Subramanian S, Karande AA, Adiga PR: Helix stabilization in the C-terminal peptide of chicken riboflavin carrier protein enhances immunogenicity and prolongs contraceptive potential as an epitope-based vaccine in female rats. Biochem Biophys Res Commun (2001) 287(1):236-243.
45. Rao J, Seshagiri PB, Shetty G, Ramesh G, Adiga PR: Active immunization against riboflavin carrier protein results in peri-implantation embryonic loss leading to pregnancy termination in rats: Use of alternate adjuvants. Indian J Exp Biol (2000) 38(9):863-872.
46. Adiga PR, Subramanian S, Rao J, Kumar M: Prospects of riboflavin carrier protein (RCP) as an antifertility vaccine in male and female mammals. Hum Reprod Update (1997) 3(4):325-334.
47. Zinkernagel RM: Uncertainties - discrepancies in immunology. Immunol Rev (2002) 185:103-125.
48. Ferro VA, Stimson WH: Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine. Vaccine (1998) 16(11-12):1095-1102.
49. Talwar GP, Singh OM, Gupta SK, Hasnain SE, Pal R, Majumbar SS, Vrati S, Mukhopadhay A, Srinivasan J, Deshmukh U, Ganga S et al: The HSD-hCG vaccine prevents pregnancy in women: Feasibility study of a reversible safe contraceptive vaccine. Am J Reprod Immunol (1997) 37(2):153-160.
50. Ferro VA, Costa R, Carter KC, Harvey MJ, Waterston MM, Mullen AB, Matschke C, Mann JFS, Colston A, Stimson WH: Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effects on vaccine efficacy. Vaccine (2004):doi:10.1016/j.vaccine.2003.08. 043.
51. Esser MT, Marchese RD, Kierstead LS, Tussey LG, Wang F, Chirmule N, Washabaugh MW: Memory T cells and vaccines. Vaccine (2003) 21(5-6):419-430.
52. Brown RG, Bowen WD, Eddington JD, Kimmins WC, Mezei M, Parsons JL, Pohajdak B: Temporal trends in antibody production in captive grey, harp and hooded seals to a single administration immunocontraceptive vaccine. J Reprod Immunol (1997) 35(1):53-64.
53. Gorman SP, Levy JK, Hampton AL, Collante WR, Harris AL, Brown RG: Evaluation of a porcine zona pellucida vaccine for the immunocontraception of domestic kittens (Felis catus). Theriogenology (2002) 58(1):135-149.
54. Seferian PG, Martinez ML: Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine (2000) 19(6):661-668.
55. Griffin PD: Immunocontraceptive methods. Annual WHO Technical Report (1995):89-102. (qhttp://www.who.int/reproductive-health/publications/ HRP-ATRs/1995/089-102.pdf).
56. Knight J: Birth-control technology. In: The Concise Encyclopedia of the Ethics of New Technologies. Chadwick R (Ed), Academic Press, San Diego, CA, USA (2000):28-37.
57. Wajcman J: Feminism Confronts Technology. Polity Press, Cambridge, UK (1991).
58. Richter J: Vaccination Against Pregnancy: Miracle or Menace? Zed Books, London, UK (1996).
59. Mordini E: Immunocontraception: The new ethical challenge: Ethical, legal, and social aspects of vaccine research and vaccination policies in Europe. In: Archives of Clinical Bioethics. Gindro S, Mordini E (Eds), CIC Edizioni Internazionali, Rome, Italy (1999):23-26.
60. Gupta A, Chandrasekhar S, Pal R, Ahlawat S, Singh O: High expression of human chorionic gonadotrophin β-subunit using a synthetic vaccinia virus promoter. J Mol Endocrinol (2001) 26(3):281-287.
61. Harrison PF, Rosenfield A (Eds): Contraceptive Research and Development: Looking to the Future. Institute of Medicine, National Academy Press, Washington, DC, USA (1996). (http://www.nap.edu/books/0309054427/html/ index.html).